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We have developed a totally new class of nonporphyrin photodynamic therapeutic agents with a specific focus on two lead
candidates azadipyrromethene (ADPM)01 and ADPM06. Confocal laser scanning microscopy imaging showed that these
compounds are exclusively localised to the cytosolic compartment, with specific accumulation in the endoplasmic reticulum and to a
lesser extent in the mitochondria. Light-induced toxicity assays, carried out over a broad range of human tumour cell lines, displayed
EC50 values in the micro-molar range for ADPM01 and nano-molar range for ADPM06, with no discernable activity bias for a specific
cell type. Strikingly, the more active agent, ADPM06, even retained significant activity under hypoxic conditions. Both photosensitisers
showed low to nondeterminable dark toxicity. Flow cytometric analysis revealed that ADPM01 and ADPM06 were highly effective at
inducing apoptosis as a mode of cell death. The photophysical and biological characteristics of these PDT agents suggest that they
have potential for the development of new anticancer therapeutics.
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Photodynamic therapy (PDT) is an emerging technique for the
treatment of cancer and noncancerous conditions (Sharman et al,
1999; Dolmans et al, 2003). It involves the administration of a
photosensitiser, followed by its excitation with low-energy tissue-
penetrating light. The interaction of the photosensitiser and light
results in photochemical production of activated oxygen species
that attack key structural entities within the targeted cells. The
most important of these oxygen species is widely believed to be
singlet oxygen (1O2) (Weishaupt et al, 1976).
1O2 has a short half-
life (0.6 106 s) and an approximate diffusion distance of 0.1 mm
in aqueous media (Moan and Berg, 1991). As such, PDT has the
potential to be a highly localised and selective form of cancer
therapy, since only irradiated areas are affected, provided the
photosensitiser is nontoxic in the absence of light.
Reactive singlet oxygen is capable of causing direct tumour cell
killing, vascular shutdown and local damage by recruitment of
inflammatory and immune mediators (Henderson and Dougherty,
1992). The efficacy of PDT is influenced by several factors
including the type of photosensitiser, its intracellular localisation,
dose of photosensitiser, light dose and fluence rate, oxygen
availability and time between administration of the photosensitiser
and light exposure (Dolmans et al, 2003). PDT can result in either
apoptotic or necrotic cell death, with this appearing related to the
specific subcellular localisation of the PDT agent (Noodt et al,
1996, 1999).
Photofrin was the first and, at the moment, remains the most
common, clinically used PDT agent (MacDonald and Dougherty,
2001). It has been approved for use in the United States, Canada
and Japan for the treatment of oesophageal, endobroncheal,
bladder, lung, stomach, cervical and skin cancers (Dolmans et al,
2003). Despite its clinical use, Photofrin is not an ideal
photosensitiser, as it is an undefined mixture of dimeric and
oligomeric compounds derived from the acid treatment of
haematoporphyrin. Many attempts to develop other photosensi-
tisers have primarily focused on poly-pyrrole macrocycles, such as
porphyrins and phthalocyanines.
The investigation of non-porphyrin photosensitisers for the
development of novel PDT agents has been considerably less
extensive (Wainwright, 1996). Development of such agents
may identify compounds with improved efficacy, reduced side-
effects and increased possibilities for modification. In this
context, we have developed a family of novel PDT agents, the
BF2-chelated tetraaryl-azadipyrromethenes (ADPM). We have
previously demonstrated that the ADPM class of compounds
display excellent photochemical and photophysical properties
(Gorman et al, 2004). Moreover, the synthesis of these com-
pounds is straightforward and results in defined single compounds
with the ability to optimise key photophysical characteristics.
Herein, we examine in detail the biological activity of two members
of this family of photosensitisers, ADPM01 and ADPM06
(Figure 1A).
MATERIALS AND METHODS
Cells
All cell lines unless otherwise stated were obtained from the
American Type Culture Collection. HeLa, MRC5, HT-1080,
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MDA-MB-231, MCF-7 and T47-D cells were cultured in minimum
essential medium (MEM) supplemented with 10% (v v1) foetal
calf serum (FCS), 1% (v v1) non-essential amino acids, 50 U ml1
penicillin, 50mg ml1 streptomycin, 20 mM HEPES and 1% (v v1)
L-glutamine (Gibco-BRL). SW480, SW620 (obtained from Professor
D Croke, Royal College of Surgeons, Dublin), A2780 and A2780cp70
cells (Obtained from Professor R Brown, Cancer Research UK,
Beatson Laboratories, Glasgow) were cultured in RPMI-1640
medium plus the above-mentioned supplements. All cells were
maintained in 5% CO2 (v v
1) and 21% O2 (v v
1) at 371C unless
otherwise stated.
Hypoxia
Cells were exposed to low oxygen conditions in a hypoxia chamber
(Coy Labs). Exponentially growing cells plus media were
equilibrated in the hypoxia chamber for 24 h. The hypoxia
chamber consisted of an airtight glove box, with the atmosphere
continuously monitored by an oxygen analyser. An oxygen
concentration of 1% was maintained throughout the chamber,
with the balance comprised of 5% CO2, nitrogen and water vapour
from a humidified chamber.
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Figure 1 Structural and spectral characteristics of ADPM series. (A) Chemical structures of ADPM01 and ADPM06. (B) Overlaid UV–Visible spectrum
(yy), fluorescent spectrum (——) and intracellular fluorescent spectrum (- - - - -) of formulated ADPM01. (C) Confocal lambda profile (wavelength scan)
of ADPM01 in HeLa cells (scale bar indicates 6 mm).
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Photosensitising agents
The synthesis of the ADPM family of compounds has been
described previously (Gorman et al, 2004). The photosensitiser
(1.3 105 mol) was dissolved in 2.0 ml of dry THF. A pre-
prepared mixture of Cremophor EL (CrEL)/1,2-propanediol
(10 : 3 v v1) (0.2 ml) was added to the solution and placed in a
sonic bath, under N2, for 1 h. The THF was removed under reduced
pressure and the remaining mixture was slowly dissolved in
phosphate-buffered saline (PBS) solution (15 ml). This solution
was then passed through an Acrodisc 25 mm syringe filter (with
0.2mm HT Tuffryn membrane) and transferred to a volumetric
flask where the solution was made up to 25 ml with PBS solution.
Dilutions into MEM containing 10% (v v1) FCS were used for
assaying. The exact concentration of the photosensitiser was
confirmed by UV –Visible spectral analysis of the solutions prior
to assaying. The quantity of CrEL/1,2-propanediol in an assayed
photosensitiser solution was always less than 0.03%.
Uptake and clearance studies
Cells were seeded at 30 000 cells well1 in chamber slides and
allowed to adhere for 24 h. For the uptake studies, ADPM01
(1 105 M) was then added to each chamber and incubated at
371C in the dark. Following appropriate incubation periods
(5 min –6 h), the cells were washed four times with media to
remove all free photosensitisers. The cells were then fixed with
3.7% formaldehyde/PBS for 15 min at 371C, after which the cells
were washed twice with PBS. Mounting fluid (Vectashield) and a
coverslip were then placed on each slide. For the clearance studies,
the cells were incubated at 371C with ADPM01 (1 105 M) for 3 h
in the dark. In this case, the cells were fixed at various time points
(15 min – 24 h) after removal of the drug. The slides were then
viewed using an Axio fluorescent microscope (Zeiss). A DAPI filter
(Band pass 356) was used to accurately count the number of cells
in each field of view and a rhodamine filter (Long pass 590) was
used to quantify fluorescence from ADPM01. LabWorks version
4.0 (Bioimaging Systems) was used to calculate the average
fluorescence intensity of ADPM01 per cell.
Confocal laser-scanning microscopy
Cells, grown on eight-well chamber slides (Nunc), were incubated
in the dark at 371C with 1 105 M ADPM01 for 1 h. The medium
was removed and the cells then treated with 250 nM MitoTracker
Green (Molecular Probes) or 100 nM ER Tracker Blue (Molecular
Probes) for 25 min. Prior to visualisation, excess probe was washed
off by rinsing in PBS four times and cells were fixed in 3.7%
formaldehyde/PBS. Cells were mounted as above and image
analysis was performed using a LSM510 META confocal laser-
scanning microscope (Zeiss) equipped with an  40 numerical
aperture 1.0 objective, with a pinhole of 100mm in diameter being
used to capture each image at a resolution of 512 512 pixels.
MitoTracker Green was excited by a 488 nm argon laser and ER
Tracker Blue was excited by a UV laser (364 nm), while ADPM01
was excited by a 543 nm helium neon laser. For simultaneous
detection of MitoTracker Green and ADPM01, a 560 nm long pass
filter was used in channel 1 (red) for ADPM01, while a 505–530 nm
band pass filter was used in channel 2 (green) for MitoTracker
Green. For dual detection of ER Tracker Blue and ADPM01, a long
pass filter of 560 nm was used in channel 1 (red) for ADPM01 and a
385– 470 nm band pass filter was used in channel 2 (blue) for ER
Tracker Blue. Using the confocal microscope, single-channel
lambda scans were performed (a long pass filter of 560 nm was
used in channel 1 (red) for ADPM01), in order to facilitate spectral
characterisation of ADPM01 compound within cells. Cell imaged
with a lower concentration of ADPM01 (5 106 M) gave similar
localisation profiles.
Colorimetric survival assay
Cells were seeded in 96-well flat-bottomed microtitre plates
(5000 cells well1) and incubated at 371C in a 5% CO2 incubator
for 24 h. Cells were then incubated with varying concentrations of
photosensitiser (1 109 to 1 104 M) in the dark for 3 h at 371C.
The ADPM compound-laden medium was then removed, the cells
were washed with PBS and fresh culture medium was added to
each well. This was followed by light irradiation with a broad-
spectrum red light source (600–750 nm) via a Waldmann
PDT1200L light delivery system. For this study, fluences (light
exposures) of either 8 or 16 J cm2, at a dose rate of 80 mW cm2,
were used. Following irradiation, the cells were incubated for a
further 48 h before being assessed for cell viability by a standard
MTT assay (Sigma). The subsequent colour change produced by
viable cells was quantified using a plate reader (VICTOR2 1420
multilabel HTS counter, Wallac). Potential toxicity attributed to
the vehicle, CrEL/1,2-propanediol, was found to be minimal. Every
experiment had an internal control, whereby no photosensitiser
was administered to the cells and results were expressed as %
control, which were irradiated along with the treated cells. The
dark toxicity of each compound was also assessed.
For cell viability experiments performed under hypoxic condi-
tions, cells were cultured in a hypoxia chamber as described above.
Varying concentrations of ADPM compounds were made using
medium equilibrated within the hypoxic environment. After 3 h,
the medium containing photosensitiser was removed, the cells
were washed with PBS to remove excess compound and fresh,
equilibrated medium was added to each well. This was followed
by light irradiation under hypoxic conditions with the broad-
spectrum red light source as before.
Flow cytometric assessment of apoptosis
Evaluation of apoptotic and necrotic cell populations was achieved
using the ApoTarget Annexin-V FITC Apoptosis kit (BioSource
International, Inc.). Cells (2.0 105) were seeded into 25 cm2 flasks
and treated with either ADPM01 or ADPM06 at respective EC50 or
10-fold EC50 concentration levels for 3 h, followed by irradiation
with red light at 16 J cm2, as described above. Subsequently, cells
were incubated for 4 and 16 h, with floating and adherent cells
being collected at each time point by centrifugation and then
stained with Annexin-V and propidium iodide (PI) as per the
manufacturer’s instructions. The percentage of cells at different
phases of cell death, namely nonapoptotic (Annexin-V/PI), early
apoptotic (Annexin-Vþ /PI), and necrotic or late-stage apoptotic
(Annexin-Vþ /PIþ ), was quantified using a EPICS XL-MCL flow
cytometer (Coulter) and analysed using System II software, with at
least 5000 cells being analysed for each run.
Visualisation of apoptosis by immunofluorescence
microscopy
Cells (1.5 104 cm2) were seeded into chamber slides for 24 h,
treated with drug for 3 h and exposed to red light at 16 J cm2, as
described above. After 16 h, cells were washed in PBS, fixed on
coverslips with 3% formaldehyde in cell culture medium for
20 min at room temperature and washed three times with PBS. The
cells were then permeabilised for 10 min with 0.2% Triton X-100 in
PBS and washed three times with PBS. Fixed cells were
subsequently co-stained with 400 mU ml1 of rhodamine phallodin
(Molecular Probes) for 30 min to stain for F-actin and, thereafter,
stained with 1 mg ml1 DAPI for 10 min. After being washed
thoroughly, cells were mounted and viewed at magnification  63
with a Zeiss Axioplan imaging microscope, with images
being obtained using Zeiss AxioCam at a resolution of
1300 1030 pixels.
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Data analysis
Prism (Bioimaging Systems) was used to graph the data obtained
from the MTT assays and the uptake/clearance experiments. This
program allows nonlinear regression analysis and the generation
of sigmoidal dose–response curves. Prism also automatically
calculates EC50 values. Statistical analysis was performed using the
ANOVA test (Prism). Significant differences were detected using
the Bonferroni multiple comparison test. P-values o0.05 were
considered statistically significant.
RESULTS
Structure and formulation of ADPM01 and ADPM06
The chemical structure of the ADPM class of photosensitiser is
unique and differs significantly from other classes of poly-pyrrole
macrocycles (Figure 1A). For drug delivery purposes, defined
solutions of ADPM01 and ADPM06 in PBS were generated using
the emulsifier CrEL. CrEL is a non-ionic surfactant, frequently
used in vivo as a delivery agent for poorly water-soluble anti-
cancer drugs such as Paclitaxel (Gelderblom et al, 2001). New
photosensitiser formulations were made immediately prior to use
and filtered to ensure homogeneity. Photosensitiser concentration
following formulation was determined by UV–Visible spectral
analysis of the solutions prior to use. The absorbance spectral
characteristics of formulated ADPM01 and ADPM06 are optimal
for use in PDT applications, with strong absorbance bands at 658
and 683 nm, respectively (Gorman et al, 2004). Analysis of
intracellular fluorescence spectra of ADPM01 using confocal
laser-scanning microscopy gave almost an identical fluorescence
spectrum compared to the aqueous formulated solution, indicating
that photosensitiser aggregation is not occurring within cells
(Figure 1B and C).
Time-dependent uptake and clearance of ADMP01
We have previously reported ADPM01 to have a high fluorescence
quantum yield (Ff¼ 0.34), which is far greater than that observed
for ADPM06 (Ff¼ 0.1) (Gorman et al, 2004). For this reason,
ADPM01 was used for all cellular imaging assays. To determine the
appropriate conditions for scheduling of light-induced cytotoxicity
assays, we determined the uptake and clearance kinetics of
ADMP01 in HeLa and MRC5 cells (Figure 2; Supplementary data).
Rapid uptake of ADPM01 in HeLa cells was observed over a 6 h
period, with 490% being accumulated by 3 h (Figure 2A). A
similar rate of uptake was seen in the case of MRC-5 cells
(Supplementary data). While clearance of accumulated ADMP01
from HeLa cells was also rapid with only 42% retention at 3 h
post-withdrawal (Figure 2B), MRC-5 cells displayed slower release
kinetics of 74% retention, 3 h post-withdrawal (Supplementary
data).
Subcellular localisation of ADPM01
It has previously been shown that ADPM01 does not localise to the
nucleus (Gorman et al, 2004). Here, we further examined the
subcellular localisation of ADPM01 in HeLa cells via confocal
microscopy using dual staining techniques. ADPM01 displayed
partial co-localisation with mitochondrial regions (Figure 3A). A
more striking co-localisation was shown for ADPM01 and the
endoplasmic reticulum (Figure 3C). Image analysis was carried out
for the localisation profile of the organelle-specific probes and
ADPM01 along the longitudinal axis of single cells. Use of
MitoTracker Green (a mitochondria-specific probe) suggested a
relatively weak accumulation of ADPM01 in mitochondria, which
is reflected in the poor overlap of a number of fluorescent peaks in
the image analysis (Figure 3B). In comparison, image evaluation of
co-localisation between ER Tracker Blue and ADPM01 revealed a
comparable pattern of localisation within the cells, with an almost
identical overlap between the transcellular longitudinal fluores-
cence localisation profiles (Figure 3D). These data appear to
strongly indicate the localisation of ADPM01 within the endo-
plasmic reticulum; however, due to their close perinuclear
proximity, additional localisation within the Golgi apparatus
cannot be ruled out.
Cytotoxic potential of ADPM01 and ADPM06
The kinetics of ADPM01 accumulation indicated an optimal
incubation time of 3 h prior to irradiation. We examined the effects
of ADPM01 and ADPM06 against a broad range of cell lines
derived from a number of different tissue types, including lung,
breast, ovary, colon and cervix (Figure 4; Table 1). In all cell lines
examined, ADPM01 and ADPM06 displayed potent cytotoxic
activity following photo-irradiation. Both compounds showed light
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Figure 2 Cellular uptake, clearance and subcellular localisation of
ADPM01 in HeLa cells. Cellular uptake (A) and clearance (B) of ADPM01
in HeLa cells over 6 and 24 h periods, respectively. Each data point
represents the mean fluorescent intensity per cell in five fields of view
(minimum of 30 cells per field of view,  20 magnification). Graphs
illustrate the average of three independent experiments. Statistics for (A),
ANOVA: Po0.0001, F¼ 10.72, Bonferroni multiple comparison test:
*Po0.01, compared to 15 min time point; **Po0.05, compared to 30 min
time point; ***Po0.05, compared to 1 h time point. Statistics for (B),
ANOVA: P¼ 0.0017, F¼ 5.46. Bonferroni multiple comparison test:
*Po0.05, compared to control, that is, immediately after removal of the
drug.
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dose-dependent cytotoxicity, with greater cell killing observed at
16 J cm2 as compared with 8 J cm2. EC50 values for each
compound varied between the different cell lines examined
(ADPM01, 2.8 106 –3.4 105 M for 8 J cm2 and 2.6 107 –
2.2 105 M for 16 J cm2; APDM06, 3.7 108 –5.4 106 M for
8 J cm2 and 1.4 108 –6.3 107 M for 16 J cm2); however, no
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Figure 3 Subcellular localisation of ADPM01. (A) Co-incubation of ADMP01 and MitoTracker Green (mitochondria-specific probe) in HeLa cells.
ADPM01 (red), MitoTracker Green (green) and overlay images shown from left to right (arrow indicates the analysed cell). (B) Longitudinal transcellular
overlay of fluorescence intensity for ADMP01 and MitoTracker Green. (C) Co-incubation of ADPM01 and ER Tracker Blue (endoplasmic reticulum-specific
probe) in HeLa cells. ADPM01 (red), ER Tracker Blue (blue) and overlay images shown from left to right (arrow indicated the analysed cell). (D) Longitudinal
transcellular overlay of fluorescence intensity for ADPM01 and ER Tracker Blue.
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apparent bias in terms of activity towards particular cell types was
observed. Notably, the A2780 cell line and its cisplatin-resistant
derivative, A2780cp70, displayed no difference with respect to
effectiveness of either ADPM01 or ADPM06 (Table 1). In a similar
vein, no distinction was seen between SW480 (colon carcinoma)
and SW620 (metastatic variant of SW480) cells in this respect. The
consistently improved efficacy of ADPM06 over ADPM01 is
attributed to the bromine substituents having a heavy-atom effect,
which results in greater efficiency of singlet oxygen generation
(Gorman et al, 2004).
ADMP06 retains activity in hypoxic conditions
The effect of hypoxia on ADPM-mediated PDT was assessed in
HeLa and MRC5 cells (Figure 5; Table 2). In both cell lines, the
efficacy of ADPM01 was completely ablated at a 1% oxygen level.
In contrast, ADPM06 displays only a partial reduction in light-
induced activity in hypoxic as compared to normoxic conditions.
In the low-oxygen environment with a light dose of 16 J cm2,
ADPM06 retains considerable efficacy, with EC50 values of 1.5 and
1.6 106 M for HeLa and MRC5 cells, respectively (Table 2).
ADPM01 and APDM06 induce apoptosis
Flow-cytometric analysis of HeLa and MRC5 cells exposed to
either ADPM01 or ADPM06 at respective EC50 values showed that
apoptosis had commenced at 4 h post-irradiation (Supplementary
data). At 16 h post-irradiation, the predominant mode of cell death
was apoptosis for both photosensitisers (Figure 6A). The induction
of apoptosis was confirmed by immunofluorescence microscopy,
which showed chromatin condensation patterns in each case, as
well as apparent apoptotic bodies (Figure 6B, circled cells).
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Figure 4 Azadipyrromethene-mediated cytotoxicity. Representative graphs illustrating the light-induced cytotoxicity of ADPM01 and ADPM06 in HeLa
and MRC5 cells for three light doses, 0 J cm2 (dark) (.), 8 J cm2 (’) and 16 J cm2 (m) in normoxic conditions.
Table 1 ADPM-mediated cytotoxicitya,b
ADPM01 ADPM06
Cell line Tissue origin EC50 (M) (dark)
EC50 (M)
(8 J cm2)
EC50 (M)
(16 J cm2) EC50 (M) (dark)
EC50 (M)
(8 J cm2)
EC50 (M)
(16 J cm2)
HeLa Cervix 2.7 105 (71.0) 2.8 106 (70.7) 9.2 107 (71.0) 4104 6.3 108 (72.0) 4.1 108 (73.0)
MRC-5 Lung 4104 3.1 106 (73.0) 5.0 107 (71.0) 4104 3.7 108 (70.3) 1.4 108 (70.1)
HT-1080 Connective tissue
from hip socket
4104 3.4 105 (70.9) 2.2 105 (74.0) 4.4 106 (74.0) 7.9 108 (71.0) 3.7 108 (75.0)
T47-D Breast 4104 5.6 106 (70.5) 5.3 106 (71.9) 4104 1.6 106 (70.8) 6.3 107 (73.3)
MCF-7 Breast 4104 3.4 106 (71.7) 1.9 106 (74.7) 4104 1.2 107 (73.1) 7.5 108 (72.1)
MDA-MB-231 Breast 1.2 105 (70.5) 5.6 106 (73.0) 2.6 107 (70.5) 4104 1.4 107 (71.9) 7.5 108 (71.2)
SW480 Colon 4104 7.6 106 (70.9) 8.0 107 (70.7) 4104 5.4 106 (71.0) 4.2 108 (70.2)
SW620 Colon 4104 5.6 106 (70.7) 2.8 106 (70.7) 4104 7.5 108 (72.9) 6.0 108 (71.1)
A2780 Ovary 4104 5.1 106 (75.1) 4.5 106 (71.2) 4104 1.0 107 (70.7) 3.5 108 (74.2)
A2780cp70 Ovary 4104 6.8 106 (73.2) 2.8 106 (72.8) 4104 6.2 108 (73.1) 2.7 108 (71.2)
aCytotoxic potential of compounds assessed in vitro using a standard MTT assay. Cells were incubated with PDT agent for 3 h prior to irradiation with 0, 8 or 16 J cm2. bMean
and standard deviation (in parenthesis) of triplicate determinations.
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Exposure of cells to a higher concentration of ten-fold EC50 level
resulted in a marked increased necrotic/late apoptotic response
being observed (Supplementary data).
DISCUSSION
PDT was first approved for clinical use in Canada in 1993, with
Photofrin being used for the treatment of bladder cancer.
Subsequently, approval has been granted in various countries for
early- and late-stage lung cancers, oesophageal, gastric and cervical
cancers. The recognised drawbacks of Photofrin are that it is an
undefined, complex mixture of haematoporphyrin derivatives,
displays poor photophysical characteristics and has a propensity to
cause long-lasting skin sensitivity due to retention in skin tissue
(Sibata et al, 2001). Uptake and clearance rates of ADPM01 suggest
that this family of photosensitisers may be clinically beneficial. In
more detail, ADPM01 is rapidly taken into tumour cells, with
490% uptake achieved within 3 h. The kinetics of cellular uptake
of ADPM01 are similar to those seen with other photosensitisers
(Khanum and Jain, 1997; Gupta et al, 2003). Of key importance,
ADPM01 is also rapidly cleared from tumour cells. Interestingly,
dark toxicity of ADPM01 was found to be limited in MRC5 cells
compared to that seen in HeLa cells, even despite slower release
kinetics in the former cell type.
Since singlet oxygen has a short half-life and can only travel
minimal distances while still retaining activity, the intracellular
distribution of photosensitisers is an important factor in
determining the efficacy of PDT (Peng et al, 1996). In recent
years, various photosensitisers have been shown to localise to the
mitochondria, lysosomes, nuclei and plasma membranes. It has
previously been demonstrated that localisation to the mitochon-
dria and endoplasmic reticulum may be beneficial in PDT terms
(Morgan and Oseroff, 2001; Teiten et al, 2003). We have shown
that ADPM01 localises to the endoplasmic reticulum and, to a
lesser extent, the mitochondria of in vitro cultured cells. The
mitochondria play a key role in energy production and calcium
homeostasis within cells. The rapid growth of tumour cells is
highly energy-dependent, so disruption to mitochondrial function
could be a significant therapeutic target. Disruption of endoplas-
mic reticulum functions relating to protein folding and calcium
storage could also be key to a PDT effect.
In the present study, we have shown that ADPM01 and ADMP06
potently inhibit the viability of a broad range of cell types, with no
apparent bias towards tumour cells of any particular tissue origin.
Moreover, isogenic drug-resistant and metastatic derivatives
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Figure 5 Azadipyrromethene-mediated cytotoxicity. Representative graphs illustrating the light-induced cytotoxicity of ADPM01 and ADPM06 in HeLa
and MRC5 cells for three light doses, 0 J cm2 (dark) (.), 8 J cm2 (’) and 16 J cm2 (m) in hypoxic (1% oxygen) conditions.
Table 2 Effect of hypoxia on ADPM-mediated cytotoxicitya
ADPM01 ADPM06
Oxygen
conditions EC50 (M) (dark) EC50 (M) (8 J cm
2) EC50 (M) (16 J cm
2)
EC50 (M)
(dark)
EC50 (M)
(8 J cm2)
EC50 (M)
(16 J cm2)
HeLa Normoxiab 2.7 105 (71.0) 2.8 106 (70.7) 9.2 107 (71.0) 4104 6.3 108 (72.0) 4.1 108 (73.0)
Hypoxiac 4104 4104 4104 4104 6.1 106 (72.2) 1.5 106 (72.0)
MRC5 Normoxiab 4104 3.1 106 (73.0) 5.0 107 (71.0) 4104 3.7 108 (70.3) 1.4 108 (70.1)
Hypoxiac 4104 4104 4104 4104 7.1 106 (72.6) 1.6 106 (71.8)
aCells were grown under either normoxic or hypoxic conditions prior to PDT, with cell viability assessed by a standard MTT assay. bNormoxia¼ 21% oxygen. cHypoxia¼ 1%
oxygen.
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displayed sensitivities to both ADPM01 and ADMP06 comparable
to that shown by their parental counterparts. Overall, this provides
strong support for the application of ADPM-mediated PDT to a
wide variety of cell types in vitro and tumours in vivo.
Cell death induced by PDT has been shown to be the result of
either apoptosis and/or necrosis (Oleinick et al, 2002), depending
on the cell type, intracellular localisation and concentration of the
photosensitiser (Kessel and Luo, 1998), as well as incubation
conditions and the light dose used (Dellinger, 1996). We have
shown that ADPM01 and ADPM06 both induce apoptosis when the
sensitiser is administered at EC50 concentration levels. It still
remains to be determined which apoptotic pathways are being
triggered by ADPM-mediated PDT. However, a combination of
mitochondrial and endoplasmic reticulum stress-induced apopto-
tic pathways would be reasonable suggestions based on subcellular
localisation data (Grebeo`ova´ et al, 2003). It is evident, however,
that induction of cell death by ADPM photosensitisers is rapid.
PDT requires molecular oxygen during light irradiation to
generate reactive oxygen species, such as singlet oxygen. In
addition to pre-existing tumour hypoxia, the process of PDT itself
induces hypoxia, as the generation of reactive oxygen species is
an oxygen-consuming process (Foster et al, 1991). PDT also causes
destruction of the microcirculation, further increasing hypoxia
within minutes (Reed et al, 1989). It is well established that
hypoxia can abolish the effect of PDT using haematoporphyrin
derivatives (Mitchell et al, 1985; Moan and Sommer, 1985). In
normal tissues, the oxygen tension is usually in the range of
5–10%, whereas in tumours values of 0 –5% are more common
(Wyld et al, 1998). Tumour hypoxia can, therefore, severely
hamper PDT efficacy. Here, we show that hypoxia completely
abolished the efficacy of the less active agent, ADPM01.
Encouragingly, the efficacy of ADPM06, which has been shown
to be a more effective singlet oxygen generator than ADPM01,
remains acceptable even under hypoxic conditions, implying a
more efficient use of the limited supply of oxygen.
Taken together, our data show the ADPM family of compounds
to be a promising new class of photosensitisers, with potent
activity against a broad range of tumour cell types. Indeed, ADPMs
appear to be more effective, especially in terms of tumour cell
destruction, than many photosensitizing agents currently available.
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Figure 6 Azadipyrromethene-mediated induction of apoptosis. (A) Induction of apoptotic cell death in HeLa and MRC5 cells by ADPM01 and ADPM06
at EC50 concentration level, 16 h post-irradiation. Cells were stained with PI and Annexin V and subsequently analysed by flow cytometry. Percentages for
each quadrant are shown. (B) Immunofluorescence assay images of ADPM-treated HeLa and MRC5 cells showing areas of chromatin condensation and
apoptotic body formation (circled cells) at 16 h time point post-irradiation (F-actin stain not shown).
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